CD8A and relapsing-remitting multiple sclerosis: Nevertheless, in this study, we showed that in vitro inhibition of DHODH alters the migratory properties of CD8 T cells in patients with RRMS, and interestingly, the velocity of CD8 T cell subsets of these patients was lower after 12 months of treatment with teriflunomide.